ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
CHAPEL HILL, N.C -- It's one of the most lethal cancers, and it affects about 20,000 Americans a year. Glioblastoma is an aggressive, fast-growing brain tumor. While there are treatments for ...
Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of ...
Updated full-year 2026 revenue guidance to $690 million to $710 million, assuming continued GBM momentum and initial ...
Novocure recently announced final results from a phase III EF-14 clinical trial of its Optune device for treatment of newly diagnosed glioblastoma (GBM). According to Novocure’s press release, the ...
The FDA has approved a lighter and more convenient version of the tumor-treating field device Optune for patients with glioblastoma multiforme. The FDA has approved a lighter and more convenient ...
LITTLETON, Colo. (CBS4)- A man with stage 4 brain cancer is beating the odds. Bruce Stahlman has extended his life expectancy with a treatment at UCHealth: a portable, painless device. He wears a ...
It’s one of the most lethal cancers, and it affects about 20,000 Americans a year. Glioblastoma is an aggressive, fast-growing brain tumor. While there are treatments for glioblastoma, there is no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results